KODK

Business Context and Reporting Period

Company: Eastman Kodak Company
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1993
Business Overview: Kodak operates primarily in three segments: Imaging (photographic films, papers, cameras, and processing), Information (graphic arts, microfilm, copiers, and printers), and Health (pharmaceuticals, consumer health, and radiography products).
Major Corporate Action: On December 31, 1993, the Company completed the spin-off of its worldwide chemical business (Eastman Chemical Company) as a dividend to shareholders. The Chemicals segment is now reported as a discontinued operation.

Key Financial Metrics

Segment Performance (1993 Sales):

• Imaging: $7,257 million (Down 2% vs. 1992)
• Information: $3,862 million (Down 5% vs. 1992)
• Health: $5,249 million (Up 3% vs. 1992)
• Chemicals (Discontinued): $3,976 million (Up 1% vs. 1992)

Material Changes vs. Prior Period

• Net Loss vs. Profit: The Company reported a net loss of $1,515 million in 1993 compared to net earnings of $1,146 million in 1992. This reversal was primarily driven by a non-cash, after-tax charge of $2,168 million ($6.60 per share) resulting from the adoption of new accounting standards (SFAS No. 106 and SFAS No. 112) regarding postretirement benefits.
• Restructuring Costs: Continuing operations incurred $538 million in restructuring costs in 1993 (after-tax impact of $379 million), compared to $220 million in 1992. These costs were associated with a workforce reduction of approximately 10,000 employees and the closure of a facility in Germany.
• Spin-Off Impact: The Chemicals segment was spun off. While sales from this segment increased slightly, the transaction involved the assumption of $1.8 billion in debt by the new entity, which was used by Kodak to retire other indebtedness.
• Operating Earnings: Earnings from continuing operations before extraordinary items and accounting changes declined to $475 million from $727 million in 1992, reflecting higher restructuring costs and increased retiree health care expenses.

Guidance, Outlook, and Risks

Management Commentary:

• Outlook: Management projects that operating cash flows will be adequate to support normal operations, planned capital expenditures, and dividend payments in 1994.
• Dividends: The Company declared cash dividends of $2.00 per share for 1993, consistent with the prior two years.
• Debt Management: The Company announced the redemption of zero coupon convertible subordinated debentures due 2011 in April 1994, requiring approximately $1.15 billion.

Risks and Contingencies:

• Environmental Liabilities: Kodak is subject to significant environmental regulations. The Company has accrued $84 million for remediation costs at year-end 1993. Future expenditures for the Kodak Park site in Rochester, NY, and compliance with the Clean Air Act Amendments could be significant but are not currently estimable.
• Legal Proceedings: The Company faces potential civil fines from the EPA regarding the Kodak Park site and is a potentially responsible party (PRP) at fewer than twenty Superfund sites, though management does not expect these costs to be material.
• Competition: Strong competition exists in all segments, particularly in traditional imaging and health care markets, driven by cost pressures and product innovation.

Investor Verification Checklist

• Accounting Change Impact: Verify the sustainability of earnings by excluding the $2.17 billion one-time charge related to SFAS No. 106/112 adoption.
• Restructuring Execution: Monitor the progress of the 10,000-person workforce reduction and the associated cash outflows in 1994.
• Environmental Exposure: Review updates on the EPA investigation of the Kodak Park site and potential future remediation costs.
• Debt Redemption: Confirm the execution of the $1.15 billion redemption of convertible debentures in April 1994.
• Segment Margins: Analyze the operating margins of the Information segment, which reported a loss of $137 million in 1993, compared to the profitable Imaging and Health segments.